Guidant shatters Johnson and Johnson stent monopoly in two months
This article was originally published in Clinica
Executive Summary
Guidant's ACS Multi-Link stent has gained a 50% share of the US market since its approval in October, with rival company Johnson & Johnson's Palmaz-Schatz stent sales falling considerably, according to one brokerage firm.